Search - tctmd.com

Displaying 1 - 20 of 86

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

L.A. McKeown

February 01, 2024

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Daily News

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

Shelley Wood

July 18, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

News Daily News

Zero CAC? LDL Cholesterol May Not Predict MI, ASCVD

Yael L. Maxwell

January 17, 2023

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Top General Cardiology and Prevention News of 2024

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

February 2024 Dispatch for the CV Team

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Mortality Risk Varies Among Patients With Very High LDL Levels

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

USPSTF: Screening Kids for Lipid Disorders Still Needs More Data

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Zero CAC? LDL Cholesterol May Not Predict MI, ASCVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content